Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 6c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($0.72), $0.06 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $13.53 million versus the consensus estimate of $11.41 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Financial Select Sector SPDR ETF (XLF) spreader of 20K contracts of July 31 weekly 57 and 59 calls into bank earnings season
• Goldman Sachs reports global fund inflows for week of July 8